Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 37, 2024 - Issue 2
Submit an article Journal homepage
115
Views
0
CrossRef citations to date
0
Altmetric
Reviews

The use of cannabinoids in palliating cancer-related symptoms: a narrative review

Jess Hatfielda Texas A&M School of Medicine, Temple, Texas, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3892-7138
, BSORCID Icon,
Krishna Sutharb Baylor Scott and White, Temple, Texas, USA
, MD,
Tricia A. Meyerb Baylor Scott and White, Temple, Texas, USA
, PharmD, MS &
Lucas Wongb Baylor Scott and White, Temple, Texas, USA
, MD
Pages 288-294 | Received 13 Sep 2023, Accepted 16 Dec 2023, Published online: 12 Jan 2024

  • Steele G, Arneson T, Zylla D. A comprehensive review of cannabis in patients with cancer: availability in the USA, general efficacy, and safety. Curr Oncol Rep. 2019;21(1):10. doi:10.1007/s11912-019-0757-7.
  • Kumar P, Mahato DK, Kamle M, et al. Pharmacological properties, therapeutic potential, and legal status of Cannabis sativa L.: An overview. Phytother Res. 2021;35(11):6010–6029. doi:10.1002/ptr.7213.
  • Arkell TR, McCartney D, McGregor IS. Medical cannabis and driving. Aust J Gen Pract. 2021;50(6):357–362. doi:10.31128/ajgp-02-21-5840.
  • FDA. FDA and Cannabis: Research and Drug Approval Process. Updated 2/23/2023. Accessed 4/19/2023. https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process.
  • Brown D, Watson M, Schloss J. Pharmacological evidence of medicinal cannabis in oncology: a systematic review. Support Care Cancer. 2019;27(9):3195–3207. doi:10.1007/s00520-019-04774-5.
  • Malhotra P, Casari I, Falasca M. Therapeutic potential of cannabinoids in combination cancer therapy. Adv Biol Regul. 2021;79:100774. doi:10.1016/j.jbior.2020.100774.
  • Woerdenbag HJ, Olinga P, Kok EA, et al. Potential, limitations and risks of cannabis-derived products in cancer treatment. Cancers (Basel). 2023;15(7):2119. doi:10.3390/cancers15072119.
  • Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 2006;24(21):3394–3400. doi:10.1200/jco.2005.05.1847.
  • Côté M, Trudel M, Wang C, Fortin A. Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Ann Otol Rhinol Laryngol. 2016;125(4):317–324. doi:10.1177/0003489415612801.
  • Hardy J, Greer R, Huggett G, Kearney A, Gurgenci T, Good P. Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). J Clin Oncol. 2023;41(7):1444–1452. doi:10.1200/jco.22.01632.
  • Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39(2):167–179. doi:10.1016/j.jpainsymman.2009.06.008.
  • Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–449. doi:10.1016/j.jpain.2012.01.003.
  • Fallon MT, Albert Lux E, McQuade R, et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain. 2017;11(3):119–133. doi:10.1177/2049463717710042.
  • Lichtman AH, Lux EA, McQuade R, et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage. 2018;55(2):179–188.e1. doi:10.1016/j.jpainsymman.2017.09.001.
  • Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20(2):567–573. doi:10.1200/jco.2002.20.2.567.
  • Frytak S, Moertel CG, O'Fallon JR, et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med. 1979;91(6):825–830. doi:10.7326/0003-4819-91-6-825.
  • Herman TS, Einhorn LH, Jones SE, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med. 1979;300(23):1295–1297. doi:10.1056/nejm197906073002302.
  • Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med. 1980;302(3):135–138. doi:10.1056/nejm198001173020302.
  • Orr LE, McKernan JF, Bloome B. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med. 1980;140(11):1431–1433. doi:10.1001/archinte.140.11.1431.
  • Einhorn LH, Nagy C, Furnas B, Williams SD. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol. 1981;21(S1):64s–69s. doi:10.1002/j.1552-4604.1981.tb02576.x.
  • Thomas J, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer. 1982;50(4):636–645. doi:10.1002/1097-0142(19820815)50:4.
  • Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE. Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat Rev. 1982;9 Suppl B:39–44. doi:10.1016/s0305-7372(82)80034-0.
  • Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage. 1991;6(6):352–359. doi:10.1016/0885-3924(91)90026-z.
  • Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23(3):533–543. doi:10.1185/030079907x167525.
  • Grimison P, Mersiades A, Kirby A, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol. 2020;31(11):1553–1560. doi:10.1016/j.annonc.2020.07.020.
  • Ware MA, Wang T, Shapiro S, Collet JP, COMPASS study team. Cannabis for the management of pain: assessment of safety study (COMPASS). J Pain. 2015;16(12):1233–1242. doi:10.1016/j.jpain.2015.07.014.
  • Bar-Lev Schleider L, Mechoulam R, Lederman V, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med. 2018;49:37–43. doi:10.1016/j.ejim.2018.01.023.
  • Maggirwar SB, Khalsa JH. The link between cannabis use, immune system, and viral infections. Viruses. 2021;13(6):1099. doi:10.3390/v13061099.
  • Bar-Sela G, Cohen I, Campisi-Pinto S, et al. Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome. Cancers (Basel). 2020;12(9):2447. doi:10.3390/cancers12092447.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.